Lymphoma News Today

Skip to content
  • Home
  • News Categories
    • Social Clips
    • Hodgkin’s Lymphoma
    • Non-Hodgkin’s Lymphoma
    • Clinical Trial
    • Leukemia & Lymphoma Society
  • About Lymphoma
    • Types Of Lymphoma
      • B-Cell Lymphoma
      • Benign Lymphoma
      • Burkitt’s Lymphoma
      • Cutaneous Lymphoma
      • Follicular Lymphoma
      • Indolent Lymphoma
      • Intestinal Lymphoma
      • Low Grade Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
    • Lymphoma Symptoms
      • Lymphedema
    • Signs Of Lymphoma
    • Lymphoma Diagnosis
    • Lymphoma Prognosis
  • Treatments
    • Approved Treatments
      • CAR T-cell Therapy
        • Kymriah (Tisagenlecleucel)
        • Yescarta (KTE-C19)
      • Adcetris (Brentuximab Vedotin)
      • Aliqopa (Copanlisib)
      • Arzerra (Ofatumumab)
      • Beleodaq (Belinostat)
      • Bendamustine in Lymphomas
      • Besponsa (Inotuzumab Ozogamicin)
      • Calquence (Acalabrutinib)
      • CPX-351
      • Gazyva (Obinutuzumab)
      • Imbruvica (Ibrutinib)
      • Keytruda for Classical Hodgkin Lymphoma (cHL)
      • Rituxan (Rituximab)
      • Rituxan Hycela
      • Revlimid (lenalidomide)
      • Velcade (bortezomib)
      • Venclexta (Venetoclax)
      • Zydelig (Idelalisib)
    • Experimental Treatments
      • ABP798 for Non-Hodgkin’s Lymphoma
      • ADCT-301 in Lymphomas
      • AFM11 for B-Cell Lymphoma
      • AFM13 for Hodgkin’s Lymphoma
      • ALT-803 for Non-Hodgkin Lymphomas
      • Betalutin
      • CMD-003 for Hodgkin’s and non-Hodgkin’s Lymphomas
      • CX-072
      • CPI-818
      • DI-Leu16-IL2
      • Duvelisib
      • GWN323
      • IGN002 for Non-Hodgkin’s Lymphoma
      • Imfinzi (Durvalumab)
      • JCAR017 for B-Cell Non-Hodgkin’s Lymphoma (NHL)
      • JCAR018
      • KTE-X19
      • Mogamulizumab
      • NM-IL-12
      • Oncoquest-L for Follicular Lymphoma
      • OXS-1550
      • PDR001 in Lymphoma
      • Resimmune
      • RG7741 (GDC-0575)
      • Tecentriq (Atezolizumab)
      • TG-1101 (Ublituximab)
      • TGR-1202 (Umbralisib)
      • Xalkori (Crizotinib)
  • Columns
    • Overcoming Adversity
    • Things That Give Me Hope
    • Life After Lymphoma: A Young Warrior’s Guide to Recovery
  • Information About COVID-19

Researchers Identify MicroRNA as Potential Target in Very Aggressive B-cell Lymphoma

April 7, 2016April 7, 2016
Margarida Azevedoby Margarida Azevedo

In News.

Researchers Identify MicroRNA as Potential Target in Very Aggressive B-cell Lymphoma

Click here to subscribe to the Lymphoma News Today Newsletter!

0
(0)

Researchers at the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have discovered a potentially new therapeutic target to treat activated B-cell diffuse large B-cell lymphoma (DLBCL).

In the study, “MiR-181a negatively regulates NF-κB signaling and affects activated B-cell like diffuse large B-cell lymphoma pathogenesis,” published in the journal Blood, the team showed that a specific microRNA called miR-181a represses NF-κB signaling and decreases cell proliferation and tumor cell survival in DLBCL, the most common form of non-Hodgkin lymphoma (NHL), accounting for up to 30 percent of newly diagnosed cases in the United States.

Thanks to genomic advances, researchers and clinicians are now able to categorize DLBCLs into two subtypes, germinal center B-cell-like (GCB) and activated B-cell-like (ABC). ABC-like DLBCLs are known to be aggressive, deadly, and resistant to chemotherapy-induced cell death. The NFκB pathway, which plays a significant role in many cancers, is partly responsible for ABC-like lymphomas’ progression and survival, due to its permanent activity. While the NFκB pathway also exists in normal B-cells, it is turned on when necessary and subsequently turned off, but it is permanently turned on in ABC-like DLBCL, leading to the cancer’s continuous growth.

Research has also discovered that ABC-like DLBCLs have less miR-181a, a critical gene regulator that, like other microRNAs, shuts down gene expression post transcriptionally. Previous research from the same group has revealed that patients whose tumors contain miR-181a have better survival outcomes.

The team, led by Izidore S. Lossos, M.D., director of the Lymphoma Program at Sylvester, studied cell lines and tumor grafts in mice, observing that miR-181a levels were significantly lower in ABC-like tumors than in GCB-like tumors. Moreover, miR-181a is a negative regulator of NF-κB signalling, and miR-181a overexpression significantly decreased the expression and activity of key NF-κB signalling genes and transcription factors, such as CARD11, a known DLBCL oncogene (a gene that is involved in tumor  progression/development).

Addition of miR-181a to ABC-like cell lines and tumor grafts reduced NFκB activity, diminished tumor growth, and significantly increased animal survival. Researchers believe that these findings explain why miR181a is biomarker for survival.

“We are trying to develop miR-181a as a potential therapy,” Lossos said in a news release, “but we are only at the beginning. Much more work needs to be done. It will not be a simple journey, but we are sure it can be done and tested in humans eventually to see that it indeed will improve patients’ outcomes.”

  • Author Details
Margarida Azevedo
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
×
Margarida Azevedo
Margarida graduated with a BS in Health Sciences from the University of Lisbon and a MSc in Biotechnology from Instituto Superior Técnico (IST-UL). She worked as a molecular biologist research associate at a Cambridge UK-based biotech company that discovers and develops therapeutic, fully human monoclonal antibodies.
Latest Posts
  • zevalin
  • Umbralisib orphan drug
  • Umbralisib orphan drug
  • CPI-818 results
Print Friendly, PDF & EmailPrint This Page

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?

Tagged biomarker, diffuse large B-cell lymphoma, DLBCL, DLBCL activated B cell-like, microRNA, miR-181a, NF-κB pathway.

Post navigation

Previous: Dr. John Leonard on When to Treat Patients with Follicular Lymphoma
Next:Harry’s Hodgkin’s Lymphoma Story

Recent Posts

  • farewell, honesty, impact, sometimes, superheroes

    A Farewell Note to My Beloved Readers

    February 26, 2021

  • farewell, honesty, impact, sometimes, superheroes

    A Light-giver Shares a Lesson in Emotional Honesty

    February 15, 2021

  • farewell, honesty, impact, sometimes, superheroes

    Embarking on a New Chapter While Cherishing the Value of Community

    February 1, 2021

Featured Posts

FDA Grants Orphan Drug Status to Umbralisib for Follicular Lymphoma

March 19, 2020

Umbralisib orphan drug

The Paradox of Healing

March 9, 2020

grateful, happiness, coronavirus, beauty
Visit Lymphoma News Today's profile on Pinterest.

Lymphoma News Today

BioNews Services, LLC
3 W Garden St
Suite 700
Pensacola, FL 32502
Email: [email protected]
Phone: +1-800-936-1363
  • About Us
  • Our Team
  • Our Guiding Ethics
  • Contact Us
  • Terms of Service
  • Privacy Policy
  • Disable Notifications

Disclaimer:

Lymphoma News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
Copyright © 2013-2022 Copyright 2015 © All rights reserved